The Business Review by Richard A. D'Errico, Web Editor
Colleen Costello’s biotech startup VitalIV is focused on eliminating common bacterial contamination in intravenous lines.
Her company is targeting an $80.2 billion market in the U.S. with products designed to reduce the incidents of patient infection and death in hospitals.
Costello, a 21-year-old senior biomedical engineering student at Rensselaer Polytechnic Institute, said the business idea was developed from a conversation with nurses at Albany Medical Center and Samaritan Hospital.
“I originally got very intrigued, passionate and interested in the medical/life sciences field when my brother was diagnosed at the age of 6 with Type 1 diabetes.
